Research coverage runs from preclinical mechanism papers to AI-driven peptide discovery. Most of what shows up here lives in Nature, Cell, Science, JAMA, and the abstracts from AACR, ESCMID, AAN, and ESCMID Global.
A few threads keep recurring. Macrocyclic and bicyclic peptides keep getting better at hitting "undruggable" targets — KRAS, beta-catenin, intracellular protein–protein interactions. Antimicrobial peptides have moved from theory to clinical candidates against carbapenem-resistant organisms and biofilms. Cancer peptide vaccines (ELI-002, autogene cevumeran, EVX-01) are producing real survival data. AI design tools — protein language models, transformer architectures, de novo platforms — are starting to generate hits that humans wouldn't.
If you want the lab side without the press releases, this is the right surface. The stories below name the lab, the journal, and the result.
Frontiers in Medicine 2026 comprehensive review on antimicrobial peptides (AMPs) as cancer treatments and vaccines synthesizes the growing body of preclinical and early-clinical evidence. Mechanism synthesis: AMPs are cationic (positively charged) amphipathic (both water-loving and lipid-loving) peptides that selectively interact with the negatively charged phospholipid outer leaflets of malignant cell membranes (produced by higher phosphatidylserine externalization in cancer cells compared to normal cells). This selectivity produces cytotoxicity through membrane disruption, followed by intracellular actions including inhibition of DNA replication and protein synthesis, induction of mitochondrial dysfunction (opening the mitochondrial permeability transition pore to release cytochrome c and trigger apoptosis), and suppression of tumor angiogenesis (reducing tumor vascular supply). The review extends the AMP-anticancer research trajectory anchored by the August 7, 2026 Nature aMPC16-CA50 synthetic acid-responsive membranolytic peptide study and recent MDPI Antibiotics coverage of frog-skin AMP families (dermaseptins from Phyllomedusa frogs, temporins from Rana temporaria, brevinins from Rana and Sylvirana). Ongoing translation challenges include high systemic toxicity at effective anticancer doses (requiring tumor-selective delivery), poor systemic stability (peptidase degradation in blood), limited cellular penetration (large hydrophilic molecules), and costly synthesis (multi-step solid-phase peptide synthesis at gram-scale). Mechanism diversity across natural-origin, synthetic (using natural templates), and AI-designed AMPs (using machine learning to design novel sequences with optimized properties) continues to expand the therapeutic pipeline.
Cancer peptide vaccine clinical trial registrations increased 34% year-over-year through mid-2026 with 78 tracked personalized cancer vaccine trials (70 Phase 1, 8 Phase 2), of which 56 are currently active and 22 have been completed. Modality breakdown: peptide vaccines represent the most-tested category at 31 trials (39.7% of the field), followed by dendritic cell vaccines at 15 trials (19.2%) and RNA vaccines at 13 trials (16.7%). Peptide vaccines target CD8+ T-cell responses (cytotoxic T cells that directly kill tumor cells) or CD4+ T helper cell responses (immune coordination) against tumor-associated antigens (TAAs, proteins overexpressed in cancer versus normal tissue) or tumor-specific antigens (TSAs, mutation-derived neoantigens unique to individual patient tumors). Indication trend: the majority of newly-registered trials target solid tumors previously considered resistant to peptide therapies (pancreatic, colorectal, triple-negative breast cancer) rather than the historically peptide-friendly indications (melanoma, glioblastoma). Combination-therapy trend: paired regimens of checkpoint inhibitor antibodies (anti-PD-1, anti-PD-L1, anti-CTLA-4) with peptide vaccines are the fastest-growing category, based on the biology that peptide vaccines can convert immunologically cold tumors to hot (increased tumor-infiltrating lymphocytes) prior to checkpoint blockade, potentially expanding the checkpoint responder population.
Real-world evidence for Wegovy (semaglutide 2.4 mg once weekly subcutaneous injection) documents 5.9% to 12% mean body weight reduction at 6 to 12 months across registry and claims analyses. This compares to 14.9% weight loss in the STEP-1 registrational trial that supported the FDA approval. The gap is primarily adherence-driven: missed doses, titration pauses, insurance-driven dose changes, and stop-restart cycles flatten real-world curves relative to the tight-adherence STEP-1 population. Cleveland Clinic research confirmed that injectable obesity medications produce smaller weight loss in a real-world setting compared to randomized clinical trials, with the gap larger in patient subgroups facing financial barriers to consistent supply. A large real-world study of nearly 8,000 patients who discontinued GLP-1 therapy found that most manage to keep the weight off or continue losing by restarting treatment, switching medications (typically to tirzepatide or higher-dose Wegovy), or adopting lifestyle changes. Patient satisfaction is driven primarily by perceived effectiveness rather than tolerability: effective weight loss even with gastrointestinal side effects is associated with continued treatment adherence, while lower-efficacy responses lead to early discontinuation regardless of tolerability. The real-world evidence has implications for retatrutide's likely commercial trajectory: the 28.7% Phase 3 ceiling may translate to 15-20% in real-world use depending on adherence patterns, which is still substantially above semaglutide's real-world 5.9-12% range.
MDPI Antibiotics published a review paper synthesizing the dual antimicrobial-and-anticancer activity of frog-skin-derived peptides. The paper covers three main families: dermaseptins (originally isolated from Phyllomedusa frogs and studied since the 1990s), temporins (small linear peptides typically 10-14 amino acids from Rana temporaria and related species), and brevinins (larger amphipathic peptides from Rana and Sylvirana genera). Mechanism synthesis: the peptides disrupt microbial membranes through broad-spectrum cationic amphipathic activity against multidrug-resistant bacteria while also selectively targeting cancer cells through electrostatic interactions with the negatively charged phospholipid outer leaflets that are characteristic of many cancer cell membranes. Cancer-cell membrane disruption is followed by apoptosis or necrosis induction in ways that differ from traditional cytotoxic chemotherapy. The frog-skin AMP family represents one of the most-studied natural sources of bioactive antimicrobial peptides with cross-category therapeutic potential. The review extends the broader anticancer AMP research trajectory anchored by the August 7, 2026 Nature paper on the aMPC16-CA50 synthetic acid-responsive membranolytic peptide that induces immunogenic cell death and the Frontiers in Medicine 2026 comprehensive review on AMPs as cancer therapeutics and vaccine adjuvants. Clinical translation challenges remain (high toxicity at effective anticancer doses, poor systemic stability, limited cellular penetration, and costly synthesis) but the mechanism-of-action diversity across dermaseptins, temporins, and brevinins provides a broad pipeline for continued preclinical and early-clinical work.
A University of Alberta research team published preclinical data in Cell Biomaterials on D-GK17, a human-derived antimicrobial peptide that targets bacterial and fungal biofilms. Biofilms are the sticky extracellular matrix bacterial and fungal communities create that render traditional antibiotic treatments substantially less effective; biofilm-associated infections drive a major portion of antimicrobial resistance and hospital-acquired infection burden. D-GK17 demonstrated stability, non-toxicity to human cells, and broad-spectrum activity against multidrug-resistant pathogens in the preclinical work. The team is filing a patent through the University of Alberta and developing gel and bandage delivery formulations for skin infections and cancer-treatment-related mouth ulcers (chemotherapy and radiation-induced oral mucositis is a substantial unmet-need indication in oncology). D-GK17 extends the rapidly-growing antimicrobial peptide therapeutic category, which the FDA PCAC February 2027 docket also advances via the cathelicidin (LL-37) peptide review. The AMP category is under active development across marine-derived (shrimp SALF-based), computational (MAC-AMP AI design system), and human-derived platforms, with cross-cutting applications spanning antimicrobial resistance, cancer therapy, and antiviral therapy.
Nature published a landmark anticancer peptide study on aMPC16-CA50, a synthetic acid-responsive membranolytic peptide that induces immunogenic membranolytic cell death (MCD) in tumor cells and substantially potentiates immune checkpoint blockade (anti-PD-1/PD-L1) therapy in preclinical mouse tumor models. The peptide is designed to respond to the acidic microenvironment of tumor tissue: at neutral pH the peptide remains inactive, but at the lower pH characteristic of tumor tissue (pH 6.0-6.5) the peptide undergoes conformational changes that allow it to insert into tumor cell membranes and induce membranolytic damage. The resulting cell death is immunogenic (releases damage-associated molecular patterns that alert the immune system) rather than apoptotic (which is typically immunologically silent), producing a mechanism that synergizes with checkpoint inhibitor therapy. The membranolytic mechanism differentiates aMPC16-CA50 from both traditional chemotherapy (which typically induces apoptosis) and from antibody-drug conjugates and CAR-T cell therapies. The paper extends the anticancer-peptide research trajectory that has moved through preclinical validation into early clinical translation with products including Cybrexa Therapeutics's CBX-12 (26-amino-acid peptide-drug conjugate for platinum-resistant ovarian cancer, Phase 2 ongoing) and Novartis's Pluvicto (lutetium-177 vipivotide tetraxetan, PSMA-targeting radiopeptide approved for metastatic prostate cancer).
A CROI 2026 (Conference on Retroviruses and Opportunistic Infections) analysis presented earlier in 2026 documented that GLP-1 weight-loss medications generally work well for people living with HIV who are stable on antiretroviral therapy. Beyond the known obesity and type 2 diabetes benefits, the CROI analysis reported potential improvements in liver, gut, and cardiovascular health, plus reduced smoking rates in the HIV population on GLP-1 therapy. Real-world analysis of people living with HIV prescribed semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound) documented comparable weight loss to general-population Phase 3 trial data with no new safety signals specific to the HIV population. Approximately 40% of people living with HIV in the US also have obesity, and cardiovascular disease is one of the primary drivers of morbidity and mortality in the HIV-treated population. The CROI analysis supports GLP-1 therapy as a reasonable consideration in HIV patients with obesity or metabolic-syndrome comorbidities, particularly following the AIDS 2026 conference programming that concluded Friday July 31 in Rio de Janeiro emphasizing the sustained management of HIV alongside comorbid conditions in the current global funding-constrained environment. The finding also intersects with the ongoing peptide-adjacent HIV therapeutic landscape covered by the July 2026 Gilead-Merck ISLEND-1 and ISLEND-2 once-weekly islatravir/lenacapavir data and the Merck alimatravir monthly HIV prevention pill.
A 2026 chemistry study documented that when tirzepatide is compounded with vitamin B12 (a common differentiating additive used by compounding pharmacies to distinguish compounded products from the FDA-approved Mounjaro and Zepbound Eli Lilly formulations), the two substances can chemically bond and form a new molecule not present in the FDA-approved drug product. The finding adds to the accumulating pharmacovigilance case against compounded GLP-1 formulations, which are marketed as bioequivalent to the branded products but frequently contain non-FDA-approved additives whose long-term safety, immunogenicity, and pharmacokinetic profiles have not been characterized in registered clinical trials. Compounding-pharmacy additives often introduce impurities and reaction products that differ from the branded label chemistry. The chemistry-specific finding on tirzepatide + B12 bonding is the type of documented novel-molecule outcome that FDA safety scientists cited in the underlying rationale for the April 30, 2026 proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List. FDA Adverse Event Reporting System (FAERS) data as of July 2026: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide. The FDA 503B comment period on the exclusion closed Thursday July 30, 2026.
Medscape published an emulated randomized trial analysis on Tuesday July 28, 2026 using US insurance claims data from 2018-2023 to test whether patients with stable inflammatory bowel disease (IBD) and comorbid obesity or diabetes benefit from initiating GLP-1 receptor agonist therapy alongside their ongoing IBD treatment. The researchers used a target trial emulation design comparing patients who initiated semaglutide or tirzepatide with patients who did not. Two cohorts were analyzed: Cohort 1 comprised patients on 5-aminosalicylates or no IBD-related therapy; Cohort 2 comprised patients on immunomodulators and/or advanced therapies (biologics or small molecules). Neither cohort showed a lower risk of IBD relapse or improved safety event rates among GLP-1 initiators. The analysis pushes back against the anti-inflammatory hypothesis advanced in preclinical GLP-1 receptor agonist literature (based on animal-model reductions in gut inflammation) and against the informal clinical assumption that IBD patients with obesity or diabetes may derive an anti-inflammatory benefit from initiating GLP-1 therapy. The clinical implication: prescribers should not initiate GLP-1 receptor agonist therapy in stable IBD patients for the purpose of improving IBD outcomes. GLP-1 initiation for obesity or diabetes in this population remains reasonable when the metabolic indication justifies it independently.
JAMA Pediatrics published a UT Southwestern Medical Center retrospective cohort study Monday July 20, 2026 examining GLP-1 receptor agonist and metabolic and bariatric surgery (MBS) utilization patterns among 204,000+ US adolescents and young adults ages 13-25 treated for obesity between May 2022 and January 2026 in the Epic Cosmos electronic health record database. Key findings: the share of patients using only GLP-1 drugs rose from 88.2% (May-November 2022) to 96.1% (June 2025-January 2026); the share of patients undergoing MBS fell from 11.6% to 3.7% over the same window; combined GLP-1 + MBS use remained rare at approximately 0.2%. The study documents a substitution effect from surgical obesity treatment toward pharmacologic obesity treatment in the youth population over 44 months of coverage. Context: severe obesity currently affects approximately 9% of US adolescents ages 12-18. The findings raise questions about long-term efficacy, weight-regain risk after GLP-1 discontinuation in adolescents, and the appropriate role of MBS in adolescents whose obesity is unresponsive to GLP-1 pharmacotherapy. The study covers the pediatric analog of the earlier adult utilization-shift patterns already documented in the Kaiser Permanente and Optum electronic health record data.
US data-analytics firm nference published a real-world evidence analysis this week that compared frailty-related outcomes across three cohorts of US adults 65 and older: nearly 30,000 patients treated with Zepbound (tirzepatide) for obesity, nearly 19,000 receiving non-GLP-1 drugs for type 2 diabetes, and nearly 6,000 who underwent weight-loss surgery. Health records showed progressive declines in muscle mass and function developed in 0.16% of patients across the analysis, malnutrition in 1.6%, dehydration in 3%, and loss of appetite in 4.75%. Lead author Soundararajan's team focused on Zepbound because prior analyses linked tirzepatide with more weight and muscle loss than semaglutide (the active ingredient in Novo Nordisk's Wegovy and Ozempic). The authors said results should not discourage appropriate use of Zepbound or Wegovy in older adults and encouraged closer follow-up of older patients on GLP-1 therapy. The findings arrive as the Medicare GLP-1 Bridge (launched July 1, 2026) expands GLP-1 access to Part D beneficiaries and as prescribers weigh muscle-preservation strategies including selective androgen receptor modulators (SARMs) like Veru's enobosarm and myostatin inhibitors.
NewAmsterdam Pharma (NASDAQ: NAMS) presented obicetrapib CETP inhibitor Alzheimer's-prevention biomarker data at AAIC 2026 in London on Wednesday July 15, 2026 in a poster session (7:30 AM-4:30 PM BST at ICC Maritime Hall) titled 'CETP Inhibition for Alzheimer's Prevention: Obicetrapib's Multi-Pathway Effects on Lipid Mediated Pathophysiology' (Abstract 2026-A-5685-AAIC, Poster 0056). The Phase 3 BROADWAY cardiovascular-outcomes trial (obicetrapib as an oral, low-dose, once-daily CETP inhibitor adjunct to statin therapy) documented statistically significant reductions in absolute plasma p-tau217 versus placebo over 12 months. Full analysis set: n=1,535, p=0.025. In ApoE4 carriers (the highest-risk Alzheimer's-genetic subgroup): n=367, p=0.022. NewAmsterdam also reported favorable trends in other AD biomarkers. Obicetrapib's mechanism is CETP inhibition to raise HDL cholesterol and lower LDL, but the AD-biomarker signal supports a dual cardiovascular-plus-Alzheimer's-prevention thesis. Obicetrapib was well-tolerated in BROADWAY with safety comparable to placebo. NewAmsterdam is advancing obicetrapib toward regulatory filings on the LDL-C indication and is in EMA review with dual cardiovascular and neurology positioning.
Eli Lilly (NYSE: LLY) presented 16 Alzheimer's disease diagnostic and therapeutic research abstracts at AAIC 2026 in London (July 12-15), including anchor data on the P-tau217 blood biomarker assay. Samantha Burnham, PhD, senior research scientist at Eli Lilly, presented data showing that P-tau217 blood biomarker assays demonstrated strong rule-in performance for identifying Alzheimer's disease pathology, with results indicating that the assays performed comparably to amyloid PET (positron emission tomography) for identifying pathology in cognitively unimpaired individuals. P-tau217 is a phosphorylated fragment of tau protein released from the brain into the bloodstream during Alzheimer's disease pathology; the fragment can be measured with a standard blood draw rather than requiring the specialized PET imaging or lumbar puncture that current Alzheimer's diagnostics rely on. Blood biomarker tests and amyloid PET agents are not yet indicated for use in cognitively unimpaired individuals, but the results generate support for a potentially scalable, accessible alternative to imaging in future early-detection screening. Lilly's therapeutic AAIC 2026 slate also included updated data on donanemab (Kisunla) and the P-tau217-anchored diagnostic pathway that pairs with amyloid-directed treatment.
Rhythm Pharmaceuticals announced Wednesday July 8, 2026 that Phase 3 TRANSCEND trial results for setmelanotide (IMCIVREE), a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in the New England Journal of Medicine. TRANSCEND is the largest and longest placebo-controlled clinical trial ever conducted in acquired hypothalamic obesity, a rare and severe metabolic condition caused by damage to the hypothalamus from tumors, surgery, radiation, or trauma. The publication documents weight and hunger improvements in adult and pediatric patients aged four years and older across the treatment arm versus placebo control. IMCIVREE is already FDA-approved as a once-daily subcutaneous injection for chronic weight management in adults and pediatric patients aged four and older with acquired hypothalamic obesity, as well as for syndromic or monogenic obesity in patients with confirmed loss-of-function variants. The NEJM publication follows the earlier Kalohexis confidential IPO filing (July 7-8) on the dual MC3R/MC4R melanocortin platform, sustaining momentum around melanocortin biology as the highest-profile non-GLP-1 obesity mechanism in commercial development.
A JAMA study led by a Yale researcher, reported by STAT on July 6, had an investigator pose as a patient across 49 websites selling branded or compounded semaglutide or tirzepatide between August and December 2025. Of those, 45 sites (91.8%) issued a prescription, with a median time to prescription of one day or less and often minimal clinical evaluation. The findings sharpen concerns about telehealth prescribing standards as enforcement against compounded GLP-1s tightens.
A study in Nature Communications describes a linear antimicrobial peptide built from four D-tryptophan/D-arginine/D-lysine repeats that stays stable in the body and kills multidrug-resistant bacteria, including MRSA and Klebsiella pneumoniae. In bacterial pneumonia models, the peptide acted through membrane targeting alongside DNA binding, reactive-oxygen accumulation, and ATP depletion, showed low potential to drive resistance, and helped restore sensitivity to existing antibiotics.
Twenty days before the July 23 PCAC vote on 503A bulks list eligibility for BPC-157, the FDA staff briefing documents and independent analyst reviews converge on a consistent picture of the substance's pharmaceutical-development state. Three decades of preclinical research led primarily by Predrag Sikiric's laboratory at the University of Zagreb (200+ published rodent studies covering tendon-to-bone healing, gastric mucosal protection, and vascular regeneration) have not yielded an approved formulation, a validated human dosing regimen, or a completed Phase 2 clinical trial in any indication. Pharmacokinetic data from rat and dog studies show plasma half-life under 30 minutes after IM or IV dosing, though the biological effects (angiogenesis, anti-inflammation, tissue regeneration initiation) persist for weeks to months in animal models. A limited Phase 2 pilot evaluated oral BPC-157 in ulcerative colitis patients with preliminary data suggesting mucosal-healing improvement and clinical-symptom-score benefit, but full results have not been published in peer-reviewed form. The historical evidence base is what PCAC weighs against the July staff briefing conclusion of insufficient evidence for 503A bulks list eligibility. Several biotech companies have publicly signaled 2026 plans to develop BPC-157 analogs with improved pharmacokinetic properties for tendon repair and IBD, but no company has yet advanced an analog into IND-stage development.
A 2026 review published in Cell and Tissue Research (Springer Nature) synthesized the current understanding of brain peptides in Alzheimer's disease pathophysiology and therapeutic development. The review's central organizing distinction is between pathogenic peptide species (amyloid-β oligomers, tau-derived fragments) that drive neuronal dysfunction and endogenous neuropeptides that exert neuroprotective effects: neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and pituitary adenylate cyclase-activating peptide (PACAP) are the three best-characterized protective classes. Adjacent April 2026 IJMS review covers the same neuropeptide neuroprotection thesis with broader Parkinson's-disease applicability. Advances in peptide chemistry are enabling two distinct therapeutic strategies: aggregation inhibitors that prevent amyloid-β oligomerization, and receptor-selective neuropeptide analogues that recapitulate endogenous NPY/VIP/PACAP signaling with improved blood-brain-barrier penetration. The peptide-neurodegeneration thread runs parallel to the BioArctic-Lilly $800 million BrainTransporter pact (June 23, peptide-delivery focus), Insilico-SK Biopharm $2.5B AI-neuroimmune deal (June 22 BIO 2026 opening), and the NVG-291 PTPσ inhibitor that NervGen is preparing for Phase 3 in chronic SCI mid-2026.